Please assess the completion status of the following clinical trial:

Trial Title: COVID MED Trial - Comparison Of Therapeutics for Hospitalized Patients Infected With COVID-19

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2/PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion criteria~1. Hospitalized patient~2. Age \>= 18 years~3. Able to ingest oral medication or be administered medication via gastric tube or equivalent~4. Laboratory confirmation of SARS-CoV-2 infection within 1 week prior to randomization~5. Randomization within 72 hr of hospital admission~6. Negative pregnancy test for reproductive age women~7. Patient or LAR able to provide informed consent~Exclusion criteria~1. Allergy or intolerance to losartan or other ARBs~2. Already taking ACE or ARB (within 1 month)~3. Hypotension at time of enrollment (SBP \< 100 mm Hg)~4. Hyperkalemia (K \>/= 5.0 at time of screening or history of hyperkalemia)~5. Severe renal dysfunction (estimated GFR \< 30 ml/min at time of screening or history advanced renal disease)~6. Severe volume depletion or acute kidney injury (AKI) at time of enrollment~7. Known cirrhotic ascites~8. Known severe aortic or mitral valve stenosis~9. Known unstented renal artery stenosis~10. Co-administration with certain drugs due to CYP3A interactions if taken in \< 24 hr~11. Severe hepatic insufficiency (LFTs \> 5 times the upper limit of normal or known ESLD or cirrhosis)~12. Nausea/vomiting or aspiration risk precluding oral medications unless can be given by gastric tube~13. Pregnancy or breast feeding~14. Absence of dependable contraception in reproductive age women~15. Inability to obtain or declined informed consent

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Losartan (Type: EXPERIMENTAL): losartan 25 mg po QD X 14 days
- Placebo (Type: PLACEBO_COMPARATOR): placebo QD X 14 days

Based on this trial design, predict the completion outcome and termination type (if applicable).